UK scientists may have discovered the world's first cure for heart attacks using the same mRNA technology as Covid vaccines.
Human heart has no capacity to heal itself after a heart attack.
But with the new technique called genetic tracking - built on the same technology used to create Pfizer and Moderna's Covid vaccines - can help new heart cells replace the dead ones and instead of forming a scar, develop a new muscle tissue.
A team at King's College London tracked genetic codes called mRNAs which are injected into the heart to produce proteins that would generate healthy heart cells, Daily Mail reported.
"We are all born with a set number of muscle cells in our heart and they are exactly the same ones we will die with. Our goal has been to find a treatment that can convince surviving cells to proliferate," lead researcher Professor Mauro Giacca was quoted as saying.
"Regenerating a damaged human heart has been a dream until a few years ago, but can now become a reality.
"We are using exactly the same technology as the Pfizer and Moderna vaccines to inject micro RNAs to the heart, reaching surviving heart cells and pushing their proliferation," Giacca said.
Besides helping hearts regenerate, the mRNAs also work towards a treatment to stop cells dying during a heart attack.
Heart attack and stroke accounted for 85 per cent of 17.9 million deaths from cardiovascular diseases globally.
Scientists believe the new RNA (ribonucleic acid) therapy could revolutionise cardiovascular medicine and stop millions of heart attacks progressing towards heart failure, the report said.
The technology tested first to regenerate damaged pig hearts have so far been successful. Tests on humans are due in the next two years.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)